Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In 2017, pembrolizumab was approved for third-line treatment of PD-L1-positive Esophageal Adenocarcinoma (EAC)
The FDA has approved pembrolizumab for second-line treatment of locally advanced or metastatic esophageal cancer with PD-L1 CPS ≥ 10 in Europe and the United States
…